1. Market Research
  2. > Biotechnology
  3. > Biological Therapy Market Trends
  4. > Biological Therapy Analysis & Statistics, June 2013 (p20)

Biological Therapy Analysis & Statistics, June 2013 (p20)

24/7 Customer Support

Talk to Amrita

+44 207 1932 091

571-600 of about 700 reports

Purchase Reports From Reputable Market Research Publishers

Cytokine PharmaSciences, Inc. (formerly Cytokine Networks, Inc.) - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Cytokine PharmaSciences, Inc. (formerly Cytokine Networks, Inc.) - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • € 280
  • Company report
  • June 2013
  • by MarketLine

Project Synopsis: MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken ...

  • Industries : Biological Therapy, Investment Banking
Fraunhofer Institute for Cell Therapy and Immunology - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Fraunhofer Institute for Cell Therapy and Immunology - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • € 280
  • Company report
  • June 2013
  • by MarketLine

Project Synopsis: MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken ...

  • Industries : Biological Therapy, General Medicine and Specialty Medicine, Diagnostics, Diagnostics
International Brachytherapy s.a. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

International Brachytherapy s.a. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • € 280
  • Company report
  • June 2013
  • by MarketLine

Project Synopsis: MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken ...

  • Industries : Biological Therapy, General Medicine and Specialty Medicine, Investment Banking
Interleukin Genetics, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Interleukin Genetics, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • € 280
  • Company report
  • June 2013
  • by MarketLine

Project Synopsis: MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken ...

  • Industries : Diagnostics, Diagnostics, Biological Therapy, In Vitro Diagnostic, In Vitro Diagnostic, General Medicine and Specialty Medicine
California Stem Cell, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

California Stem Cell, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • € 280
  • Company report
  • June 2013
  • by MarketLine

Project Synopsis: MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken ...

  • Industries : Biological Therapy
  • Countries : United States
CSL Biotherapies, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

CSL Biotherapies, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • € 280
  • Company report
  • June 2013
  • by MarketLine

Project Synopsis: MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken ...

  • Industries : Biological Therapy, Therapy
Stem Cell Sciences plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Stem Cell Sciences plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • € 280
  • Company report
  • June 2013
  • by MarketLine

Project Synopsis: MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken ...

  • Industries : Biological Therapy
MorphoSys - MOR103 – Partnering is Just the Beginning of a New Phase of Growth

MorphoSys - MOR103 – Partnering is Just the Beginning of a New Phase of Growth

  • € 112
  • Company report
  • June 2013
  • by MP Advisors

Licensing of un-partnered early programs and the clinical data of its maturing therapeutic antibody pipeline are future drivers of Morphosys (MOR). After selling its services division (AbD Serotec) last ...

  • Industries : Biological Therapy
Mesenchymal Stem Cells, Advances & Applications

Mesenchymal Stem Cells, Advances & Applications

  • € 2 796
  • Industry report
  • June 2013
  • by BioInformant Worldwide, L.L.C.

Mesenchymal stem cells (MSCs) are multipotent stem cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, adipocytes, beta-pancreatic islets cells, and ...

  • Industries : Biological Therapy
Global Gene Therapy Market Analysis

Global Gene Therapy Market Analysis

  • € 960
  • Industry report
  • June 2013
  • by RNCOS

Gene therapy is the treatment of a disease by replacing, altering, or supplementing a gene that is absent or abnormal and whose absence or abnormality is causing the disease. It has evolved as one of the ...

  • Industries : Biological Therapy, Biotechnology, Pathology
  • Countries : United States
Recombinant Coagulation Factors 2013 – The Race to Market and for Market Shares: A Technology & Pipeline Assessment and Corporate Benchmarking Analysis

Recombinant Coagulation Factors 2013 – The Race to Market and for Market Shares: A Technology & Pipeline Assessment and Corporate Benchmarking Analysis

  • € 2 150
  • Industry report
  • June 2013
  • by La Merie Publishing

A Technology & Pipeline Assessment and Corporate Benchmarking Analysis The report “Recombinant Coagulation Factors 2013 – The Race to Market and for Market Shares: Technology & Pipeline Assessment ...

  • Industries : Biopharmaceutical, Biotechnology
  • Countries : Europe, United States
Asia-Pacific Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) – Forecast to 2017

Asia-Pacific Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) – Forecast to 2017

  • € 3 720
  • Industry report
  • May 2013
  • by MarketsandMarkets

The radiopharmaceuticals market in the Asia-Pacific region was valued at $500.8 million in 2012; it is poised to reach $824.9million in 2017 at a CAGR of 10.5%. The market is broadly classified into two ...

  • Industries : Diagnostics, Diagnostics, Medical Imaging, Medical Imaging
  • Countries : Asia, World
ASCO ’13 - Promise of Novel Targets/Technologies to Unfold At ASCO 2013

ASCO ’13 - Promise of Novel Targets/Technologies to Unfold At ASCO 2013

  • € 112
  • Company report
  • May 2013
  • by MP Advisors

New cancer therapies are being developed through targeted approaches that can accelerate development of more efficacious, personalized treatments. Data from such novel targets or technologies (BTK/ PI3K/ ...

Cytokine PharmaSciences, Inc. – Product Pipeline Review – 2013

Cytokine PharmaSciences, Inc. – Product Pipeline Review – 2013

  • € 1 200
  • Company report
  • May 2013
  • by Global Markets Direct

Cytokine PharmaSciences, Inc. – Product Pipeline Review – 2013 Summary Global Market Direct’s pharmaceuticals report, “Cytokine PharmaSciences, Inc. - Product Pipeline Review - 2013” provides ...

  • Industries : Biological Therapy
iPS cell Differentiation patent landscape - 2013/03

iPS cell Differentiation patent landscape - 2013/03

  • € 2 900
  • Industry report
  • May 2013
  • by France Innovation Scientifique et Transfert

Many diseases such as cardiovascular disorders, diabetes or neurodegenerative diseases are the consequences of dysfunction of specific cells. Strategies were developed to repair or regenerate the damaged ...

  • Industries : Biological Therapy
Competitor Analysis: Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors

Competitor Analysis: Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors

  • € 1 600
  • Industry report
  • May 2013
  • by La Merie Publishing

Product Description The new Competitive Intelligence Report Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors of May 2013 provides a competitor analysis of the product portfolios and ...

  • Industries : Biopharmaceutical, Biotechnology
The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities

The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities

  • € 2 560
  • Industry report
  • May 2013
  • by BioInformatics

Study Objectives This study of the academic and pharma/biotech sectors in North America and Europe will provide an analysis of the market for primary cells and an assessment of the brand equity for the ...

  • Industries : Battery, Biological Therapy
Blood Disease Treatment Drugs Markets in China

Blood Disease Treatment Drugs Markets in China

  • € 3 200
  • Industry report
  • May 2013
  • by Asia Market Information & Development Company

China's demand for blood treatment disease drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic ...

  • Industries : Pharmaceutical, Pathology
  • Countries : China
European Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) – Trends & Forecast to 2017

European Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) – Trends & Forecast to 2017

  • € 3 720
  • Industry report
  • April 2013
  • by MarketsandMarkets

Radiopharmaceuticals are drugs that contain radionuclide-emitting ionizing radiation, used in the nuclear imaging field to diagnose and treat diseases. The European radioisotopes market was valued at $1.1 ...

  • Industries : Diagnostics, Diagnostics, Medical Imaging, Medical Imaging
  • Countries : Europe
Molecular Diagnostics Market & Forecast (By Application, Technology, Countries, Companies & Clinical Trials) to 2017: Global Analysis

Molecular Diagnostics Market & Forecast (By Application, Technology, Countries, Companies & Clinical Trials) to 2017: Global Analysis

  • € 1 120
  • Industry report
  • April 2013
  • by Renub Research

Global Molecular Diagnostics Market & Future Forecast to 2017 Overview The global molecular diagnostics market is witnessing a period of profound growth. The growth is coming from different regions and ...

  • Industries : Diagnostics, Diagnostics, In Vitro Diagnostic, In Vitro Diagnostic, Biotechnology, Biological Therapy, Medical Devices
  • Countries : World
Nuclear Medicine/Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) Market - Global Trends & Forecast to 2017

Nuclear Medicine/Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) Market - Global Trends & Forecast to 2017

  • € 3 720
  • Industry report
  • April 2013
  • by MarketsandMarkets

The market of radiopharmaceuticals is dominated by diagnostic radioisotopes, comprising of SPECT and PET radioisotopes. The lion’s share of the SPECT market is taken up by Tc-99m, whereas the PET market ...

  • Industries : Diagnostics, Diagnostics, Medical Imaging, Medical Imaging
  • Countries : World
Competitor Analysis: G-CSF and GM-CSF

Competitor Analysis: G-CSF and GM-CSF

  • € 400
  • Industry report
  • April 2013
  • by La Merie Publishing

Product description The present Competitive Intelligence Report about G-CSF and GM-CSF product portfolios and R&D pipelines provides a competitor evaluation in the field of G-CSF & GM-CSF branded products ...

  • Industries : Biological Therapy, Biotechnology
Competitor Analysis: Interferon

Competitor Analysis: Interferon

  • € 450
  • Industry report
  • April 2013
  • by La Merie Publishing

Product description The Competitive Intelligence Report Interferon as of April 2014 provides a competitor analysis in the product portfolios and development pipelines of novel recombinant and natural interferon ...

  • Industries : Biological Therapy
Regenerative Medicine Markets

Regenerative Medicine Markets

  • € 2 720
  • Industry report
  • March 2013
  • by TriMark Publications

Regenerative medicine is a way of treating injured and diseased human tissue by using laboratory-grown or therapeutically-induced human tissue as a replacement. As such, astounding new advancements in ...

  • Industries : Biological Therapy, Biotechnology, Pharmaceutical, Healthcare
  • Countries : United States, World, North America
Natural Killer Cell Lymphomas – Pipeline Review, H1 2013

Natural Killer Cell Lymphomas – Pipeline Review, H1 2013

  • € 1 600
  • Industry report
  • February 2013
  • by Global Markets Direct

Natural Killer Cell Lymphomas – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Natural Killer Cell Lymphomas - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic ...

  • Industries : Biological Therapy, Drug and Medication
  • Countries : World
Therapeutic Class Report Overview - Rituxan Biosimilar

Therapeutic Class Report Overview - Rituxan Biosimilar

  • € 1 600
  • Company report
  • February 2013
  • by MP Advisors

The growth in the biosimilar opportunity will be driven by several patent expiries of mega-blockbuster biologics in the next 5 years. Between 2012 and 2017, over $60b worth of sales of biologics in the ...

  • Industries : Biological Therapy
  • Countries : Europe
In-Vitro Diagnostics Market Analysis to 2017

In-Vitro Diagnostics Market Analysis to 2017

  • € 1 200
  • Industry report
  • February 2013
  • by RNCOS

The global in-vitro diagnostics (IVD) market is going through a very exciting phase, offering immense opportunities for players involved in the business. The market, which on one hand, is struggling to ...

  • Industries : Diagnostics, Diagnostics, In Vitro Diagnostic, In Vitro Diagnostic
  • Countries : World, Europe, United States
ROCHE, Confidence building up on next gen. Rituxan (GA101)

ROCHE, Confidence building up on next gen. Rituxan (GA101)

  • € 72
  • Company report
  • January 2013
  • by MP Advisors

Roche seems to be on track of delivering sustainable growth as it announced today that Obinutuzumab (GA-101), follow-on biologic to Rituxan has demonstrated significant improvement of PFS against chemotherapy ...

  • Industries : Biological Therapy, Biotechnology, Biopharmaceutical
The 2013-2018 Outlook for Cancer Therapy Pharmaceuticals in Japan

The 2013-2018 Outlook for Cancer Therapy Pharmaceuticals in Japan

  • € 396
  • Industry report
  • January 2013
  • by ICON Group

This report does not cover the individual items, but rather the aggregate level of demand across all items within the category. This econometric study covers the latent demand outlook for cancer therapy ...

  • Industries : Biological Therapy
  • Countries : Japan
The 2013-2018 Outlook for Cancer Therapy Pharmaceuticals in the United States

The 2013-2018 Outlook for Cancer Therapy Pharmaceuticals in the United States

  • € 396
  • Industry report
  • January 2013
  • by ICON Group

This report does not cover the individual items, but rather the aggregate level of demand across all items within the category. This econometric study covers the latent demand outlook for cancer therapy ...

  • Industries : Biological Therapy
  • Countries : United States

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.